Small molecule inhibitors of α-synuclein oligomers identified by targeting early dopamine-mediated motor impairment in C. elegans

BACKGROUND: Parkinson’s disease is a disabling neurodegenerative movement disorder characterized by dopaminergic neuron loss induced by α-synuclein oligomers. There is an urgent need for disease-modifying therapies for Parkinson’s disease, but drug discovery is challenged by lack of in vivo models t...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Kevin S., Menezes, Krystal, Rodgers, Jarlath B., O’Hara, Darren M., Tran, Nhat, Fujisawa, Kazuko, Ishikura, Seiya, Khodaei, Shahin, Chau, Hien, Cranston, Anna, Kapadia, Minesh, Pawar, Grishma, Ping, Susan, Krizus, Aldis, Lacoste, Alix, Spangler, Scott, Visanji, Naomi P., Marras, Connie, Majbour, Nour K., El-Agnaf, Omar M. A., Lozano, Andres M., Culotti, Joseph, Suo, Satoshi, Ryu, William S., Kalia, Suneil K., Kalia, Lorraine V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8588601/
https://www.ncbi.nlm.nih.gov/pubmed/34772429
http://dx.doi.org/10.1186/s13024-021-00497-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8588601/
https://www.ncbi.nlm.nih.gov/pubmed/34772429
http://dx.doi.org/10.1186/s13024-021-00497-6

Ejemplares similares